

# **MINT – Malaria Intervention Tool**

Tool to guide malaria control decision making

## **User Guide**

Sherrard-Smith E, Winskill P, Hamlett A, Ngufor C, N’Guessan R, Guelbeogo M, Sanou A, Nash R, Hill A, Russell EL, Woodbridge M, Fitzjohn RG, Tungu P, Mclean, T, Fornadel, C, Richardson, J, Donnelly, M, Staedke S, Gonahasa S, Protopopoff N, Rowland M, Churcher TS.

### **Version 1**

Accompanying publication:

*Sherrard-Smith et al. 2020 Optimising the deployment of new vector control tools against malaria. In submission*

### **CONTENTS**

<b>1. BACKGROUND</b>	<b>3</b>
1.1 What is the problem?	3
1.2 What are the benefits of the tool?	3
1.3 What can the tool do?	3
1.4 What the model cannot do?	3
1.5 Model limitations and assumptions	4
1.6 What size area should be considered?	8
1.7 Where can it be found?	8
<b>2. STEP-BY-STEP USER GUIDE</b>	<b>9</b>
2.1 Set up baseline	10
2.2 Set up interventions	14
2.3 Procurement and distribution	15
2.4 Price of interventions	16
<b>3 INTERPRETATION</b>	<b>18</b>
3.1 Impact Graph	18
3.2 Impact Table	20
3.3 Cost effectiveness graph	21
3.4 Cost effectiveness table	22
<b>References</b>	<b>23</b>

Accompanying publications:

### **Meta-analyses of entomological data**

We use systematic review data analyses from previous papers to parameterise the model underpinning the webtool MINT. These are:

*Nash et al. 2021. Systematic review of the entomological impact of insecticide-treated nets evaluated using experimental hut trials in Africa. Accepted. Current Research in Parasitology and Vector-Borne Diseases*

This manuscript presents the systematic review of entomological data including World Health Organization discriminatory dose susceptibility bioassays, the Centre for Disease Control (USA) discriminatory dose susceptibility (tube and bottle) bioassays, and experimental hut trial assays. The statistical analyses are used to determine the relationship between the level of resistance (as measured by the discriminating dose bioassay) and the entomological impact of insecticide treated nets in the transmission model behind MINT.

*Killeen et al. (2017) Going beyond personal protection against mosquito bites to eliminate malaria transmission: population suppression of malaria vectors that exploit both human and animal blood. BMJ Global Health 2: e000198. Doi: 10.1136/bmjgh-2016-000198*

This manuscript summarises our understanding of the distribution in human blood feeding among mosquito species. We use these analyses to inform the 'high' and 'low' options offered in the MINT interface.

*Sherrard-Smith et al. 2019 Mosquito feeding behaviour and how it influences residual malaria transmission across Africa. PNAS 116: 15086-15096. Doi: 10.1073/pnas.1820646116*

This manuscript summarises our understanding of the proportion of mosquito feeding attempts that continue even when indoor mosquito interventions are optimally deployed and used. We use these analyses to inform the 'high' and 'low' options offers in the MINT interface.

### Transmission dynamic mathematical modelling

*Sherrard-Smith et al. 2021 Optimising the deployment of new vector control tools against malaria. Under review.*

This manuscript builds on the parameter estimates from Nash et al (2021) and explores the added benefit of using pyrethroid-PBO mosquito nets. It accompanies MINT version 1.0 and presents the model used to generate the results presented in the webtool.

*Griffin et al. 2010 Reducing Plasmodium falciparum malaria transmission in Africa: A model-based evaluation of intervention strategies. PLoS Medicine 7: e1000324*

The evidence base for the full transmission model are provided in a succession of papers that have iteratively improved the transmission model since it was first published in 2010. These include:

*White et al. 2011 Modelling the impact of vector control interventions on Anopheles gambiae population dynamics. Parasites & Vectors 4: 153*

*Griffin et al. 2016 Potential for reduction of burden and local elimination of malaria by reducing Plasmodium falciparum malaria transmission: a mathematical modelling study. The Lancet Infectious Diseases 16: 465-472*

*Churcher et al. 2016 The impact of pyrethroid resistance on the efficacy and effectiveness of bednets for malaria control in Africa. eLife 5: e16090*

*Sherrard-Smith et al. 2018 Systematic review of indoor residual spray efficacy and effectiveness against Plasmodium falciparum in Africa. Nature Communications 9: 4982*

## **1. BACKGROUND**

### **1.1 What is the problem?**

Insecticide treated mosquito nets (ITNs) and indoor residual spraying of insecticides (IRS) have been the key vector control tools for malaria in the past 20-years. Mosquitoes that transmit malaria are becoming increasingly resistant to the pyrethroid insecticide that forms the active ingredient of the traditional nets distributed on mass across malaria-endemic countries (1). Resistance to other insecticides is also increasing (2,3). In response, the global community has been developing novel vector interventions to mitigate for the diminishing protection provided by pyrethroid only long-lasting ITNs (pyrethroid LLINs).

These interventions have different prices, and different durations of activity at killing, deterring and inhibiting blood-feeding of local mosquitoes. Depending on patterns of use and local ecology, the impact of these interventions can be spatially and temporally variable. There are inevitably limits on National malaria budgets, and products with better public health benefit tend to cost more, so recommending a new product, with slightly better potential, may reduce the quantity purchased and perversely increase disease. There is a considerable challenge to determine which interventions to use in regions of the country with different population sizes, historic use of interventions, mosquito ecology and local customs, jobs or habits that may lead to varied exposure to infectious mosquito bites for residents.

### **1.2 What are the benefits of the tool?**

The novel interventions now available have contrasting public health impact given the characteristics of the local mosquito population, the level of disease and history of control interventions. The MINT tool has capacity to theoretically explore some of the potential outcomes of the deployment of multiple interventions given differences at baseline in different regions. The challenge for decision makers with limited budgets tasked with protecting communities from malaria is addressed by providing a tool within which these theoretical scenarios can be explored.

### **1.3 What can the tool do?**

Version 1 of this vector control decisions tool is designed to help National Malaria Control Programs explore the most cost-effective current World Health Organisation (WHO) recommended mosquito nets and IRS products for falciparum malaria control. Local human, mosquito and cost data are used to characterise the setting of interest (we refer to this setting as a region or zone in the tool). The tool then summarising the impact of different vector control interventions used in the region and calculates the cost effectiveness of each of the intervention packages. A maximum budget can be set to help determine the most appropriate and affordable intervention for that particular region according to local goals.

### **1.4 What the model cannot do?**

No model is as good as high-quality local surveillance data and implicit understanding from local research, which should be collected and used to inform future policy. Predictions are made using average entomological and epidemiological data from systematic reviews that gather data from


across Africa so may not be representative of all settings. For example, IRS efficacy is thought to vary according to the type of wall material which will vary from site to site (4,5) and any post-spray modifications could impact the overall performance of a product (6). These differences and uncertainties should be considered in any decision-making process. Similarly, predictions from the model are only as good as data used to parameterise them, so the simulations may be more useful where local data are well understood. Simplifications have been made (for example, in the range of endemicity settings that are explored) so individual estimates of impact and cost-effectiveness will be slightly different from reality. Nevertheless, the relative difference between intervention options is likely to be more consistent and predictions of impact have been shown to adequately reflect changes in malaria prevalence observed in the field (see main manuscript).

## **1.5 Critical modelling assumptions and limitations**

There are many assumptions that need to be communicated to help with the interpretation of modelling results. This list is not meant to be exhaustive but to highlight some of the major assumptions that will influence predictions interpretation. Users are encouraged to view the accompanying publications section above where the references therein list all assumptions made and provide their justification.

### **1.5.1 Model assumptions**

- The relationship between different malaria metrics are captured in the mechanistic model taking into account factors such as persons age, history of malaria/control interventions, local entomology and drug treatment. Simulations are parameterised for each setting of interest using local information on the prevalence of malaria in children 0-5 years old (as diagnosed by microscopy) which can be estimated from local Demographic Health Survey data. Care should be taken parameterising the model using other metrics or data collected in different age groups as results will differ. MINT cannot currently be parameterised using entomological data such as the entomological inoculation rate (EIR). The relationship between malaria prevalence, clinical incidence and EIR is outlined in Griffin et al. (2014) (7). An illustration of the relationship between EIR and malaria prevalence is provided in (Figure 1.1) though the shape of this relationship will alter depending on the alternative parameters used within the framework. We illustrate this by changing treatment levels within the community (Figure 1.1).



**Figure 1.1** The association in the transmission model between prevalence and the entomological inoculation rate changes depending on the level of treatment available. Here, the dashed line is the association when 42% of people receive treatment and 31.5% receive Artemisinin combination therapy (ACT). The solid line shows the association when 80% of people receive treatment with 60% receiving ACT.

- This model has specific parameters associated and is fully described in (8). We also provide a full description of the transmission model and assumptions on mechanisms tracking the transmission of *falciparum* malaria in the accompanying paper for MINT v1.0 (main manuscript).
- The model is explicitly for *falciparum* malaria and parameterised using data from the African continent so is currently limited for use elsewhere, or where *falciparum* is not the dominant malaria parasite.
- The model is not designed to capture near-elimination settings. The dynamics of transmission in near-elimination settings is likely to be highly context specific and dependent on re-introduced malaria from importation events (9). Estimates once malaria prevalence drops beneath 1% should be treated with caution.
- We assume the average age for the population is 21 years and that the demographic structure of the population is represented by an exponential with this average age (see WorldPop.org; (10)). This average age is based on the population age structure for Tanzania but well represented in many other settings.
- In version 1.0, mosquitoes are modelled using a compartment-based framework. This means that mosquitoes are assigned parameter values to capture only the average behaviour in any region. Therefore, the values chosen for the time at which mosquitoes bite and on humans is

constant and the same value is assumed throughout the simulation. This means that any effects are smoothed over the output rather than capturing the stochasticity that would be expected were a more realistic individualistic framework adopted (where we could assign different behaviours or assumed seasonal patterns to these parameter estimates).

- A limited set of seasonality in mosquito abundance are provided which remain the same for the three years of the simulation. If one-year results in high abundance for mosquitoes able to transmit malaria, intuitively, the performance of the mosquito nets and indoor spray would be expected to be worse than for years where abundance is lower.

### 1.5.3 Intervention assumptions

- It is assumed that entomological parameters entered into the interface remain the same for the whole simulation period. This means that the level of pyrethroid resistance will remain constant over three years and is not influenced by the choice of vector control tool deployed. This is clearly an oversimplification but given the uncertainty about the rate of change in resistance with use of nets and how insecticide use in agriculture might also influence change in mosquito susceptibility it appears the most parsimonious option. Users should do multiple runs varying the level of resistance to ensure that decisions are insensitive to plausible changes in these parameters over time.
- Mosquito nets are modelled to be distributed, overnight, to the percentage of people that the user indicates. This value is assumed to be the proportion of the population using nets each night immediately after the mass campaign. We assume that adherence to using nets wanes over time so that about half as many people are still using nets 5 years after the initial campaign as compared to the usage level set for the simulation.
- We assume that nets are distributed at random to the population, and across age-groups. The same assumption is made for IRS. Where nets and IRS are both deployed, we assume there is overlap in those people receiving both interventions. This is because we assume some people in the community are easier to reach than others. If this is not the case, we would expect the combined use of net and IRS interventions to be greater.
- We do not include product differences such as the integrity of the materials used to make the nets. We assume that for example, Olyset Plus performs equivalently to PermaNet 3.0 as 'pyrethroid PBO nets' (11).
- We assume nets have equivalent impact on mosquitoes of any species once exposure to the insecticide has happened. That is, the killing effect of the insecticide and its propensity to deter or repel mosquitoes is constant among Anopheles species. This follows a systematic review of experimental hut data (12) which found insufficient data to distinguish species specific effects. The model should be parameterised for the average mosquito vector at the site of interest as different mosquito species are not explicitly simulated. This is true also for IRS following a systematic review of IRS experimental hut trials with the same limitations on species-specific data (13).
- In (13), we estimate the average impact of IRS across all available bioassay data to date, accounting for any exophilic behaviours within the impact parameters. Therefore, if the region is suspected or known to have highly endophilic mosquitoes, we would expect the IRS to work better than, for instance a region with outdoor-resting species. The range in IRS impact shown in MINT will bridge this effect. This range is shown for each region explored. However, we do not currently account for this range in the strategization analysis and encourage the user to explore the budget (as explained in Section 4) to infer how much may be gained from adding IRS. This will be updated in future versions of MINT.

- A limitation of the current framework is that we cannot demonstrate any effect of mosquito interventions acting to reduce one species, only to have the niche filled by a another vector.
- Similar to nets it is assumed that IRS is deployed throughout the site of interest overnight. This is clearly an over-simplification as the delivery of IRS may be spread out across recipient households over a few weeks or months. In non-seasonal settings this is unlikely to change the impact predicted for long-lasting IRS products. For perennial settings, this could have some impact and will depend on where and how long it takes to deploy IRS across a region.
- We include IRS uncertainty that should broadly represent the organophosphate, pirimiphos methyl (e.g. Actellic 300®CS, Syngenta) or neonicotinoids, clothianidin (SumiShield®, Sumitomo Chemical). If the product is a bendiocarb-based, pyrethroid-based or DDT product, the MINT tool is not based on systematically reviewed data from experimental huts, so please interpret these product impacts cautiously.
- We assume independence between the effects of mosquito nets and IRS (14). That is the effects of the two interventions are multiplicative in relation to the impact on probability of successful feeding, biting or being repelled. This assumption should be further verified.
- We are only considering the distribution of nets through mass campaigns. Continual net distribution campaigns such as those through antenatal clinics or such as those adopted with success in Tanzania through school-based top-up are not considered.

#### 1.5.4 Assumptions on costs

- The cost section of the tool is relatively simplistic and does not include factors such as discounting or changes over time. Costs entered are defined by the user, allowing some degree of flexibility, though care should be taken interpreting results as costs will likely vary with other parameters. For example, it is likely that the relationship between cost and the percentage of people using a net is non-linear, i.e. it is less expensive to increase net usage from 20% to 30% than from 60% to 70% of the population (15). Users will therefore need to change the cost of net delivery (or the size of the procurement buffer) according to the usage they predict to achieve.
- Default costs are provided but we advise users to adjust these as needed (see section 2.4).
- For simplicity, we assume no costs are saved where both nets and IRS are implemented so that for combined interventions, we simply sum these costs.
- Here we consider only the costs of vector control and do not include any cost savings which might result from fewer malaria cases (for example, less money spent on malaria treatment drugs). More advanced analyses that consider these benefits are encouraged.
- Cost-effectiveness estimates will depend on the treatment and access to care for a population. Here we are considering only a scenario where X people promptly receive treatment with an artemisinin combination therapy. As we are comparing the impact of vector control within a region, as long as the same treatment scenario is applied for each comparison, the direction of impact will be the same. Different treatment rates would change the absolute estimate of malaria prevalence, cases averted, and therefore cost per case averted. Nevertheless, the directionality of which intervention was most useful i.e. ITN + IRS will always be predicted to have higher efficacy than either intervention alone. This reflects empirical data observations (16–18), but absolute estimates of the cost per case averted should be treated with care.

#### 1.6 What sized area should be considered?



A region is defined as a management unit which has similar characteristics. This could be an administration unit or province. IRS is very focal and usually completed in a smaller region of a larger province or district. The model assumes that IRS is applied at random to the population so, it is more appropriate to separate regions into IRS regions or non-IRS regions for this assessment and adjust population size accordingly.

### 1.7 Where can it be found?

The online tool can be accessed free online at <https://mint.dide.ic.ac.uk/>

#### **Key definitions**

*Intervention Class* – World Health Organization classification for a new set of malaria vector control interventions which have the same entomological model of action. To form a new intervention class new products require epidemiological evidence of benefit over standard-of-care from two cluster randomised control trials

*ITN* – Insecticide treated net where the durability of the product is undetermined

*LLIN* – Long-lasting insecticidal net. An ITN which has proven durability i.e. the lethal time until less than 50% of the initial mortality induced is at least 2 years.

*Pyrethroid LLIN* – LLIN containing pyrethroid insecticide only. Widely used since 2000 this class of interventions is now showing signs of diminished efficacy in areas with highly pyrethroid-resistant mosquitoes.

*Pyrethroid-PBO ITN* – mosquito nets which contain pyrethroids and the synergist piperonyl butoxide. A new WHO-declared intervention class for mosquito nets that kill host-seeking insecticide-resistant mosquitoes by neutralising the enzymes responsible for pyrethroid resistance; epidemiological value has been demonstrated by the first-in-class product when compared to the public health impact of pyrethroid-only nets in two RCTs (11,18) though their long-term durability in the field is presently unclear.

All model assumptions are outlined in the attached manuscript other than the variables outlined below which the user is able to define.

## 2. STEP-BY-STEP USER GUIDE

The online tool allows multiple projects to be created.

MINT

This tool is designed to help National Malaria Control Programs explore the most cost effective option of deploying current World Health Organisation (WHO) recommended ITN and IRS products for malaria control.

In this tool, a **project** is a collection of regions and a **region** is defined as a management unit - this could be an administration unit, province or village. For each region defined in the tool, there is a set of outputs summarising the impact and cost effectiveness of intervention packages.

IRS is very focal and usually completed in a smaller region of a larger province or district. The model assumes that IRS is applied at random to the population so it is more appropriate to create separate IRS regions and non-IRS regions for this assessment and adjust population size accordingly.

### You have 1 project

P1 ▾

+ Start new project

Name

Project name

Regions

First region, second region

Add multiple region names separated by commas. You can always add and remove regions later

Create

The user can choose a name for the project and define the different regions present. In this tool, a region is defined as a management region. The tool identifies the impact and cost-effectiveness of different vector control intervention combinations given the current situation for the location. For each region, the tool is described in separate input sections;

## 2.1 Setup baseline

Setup baseline

Site Inputs	Mosquito Inputs	Past Vector Control
Population Size <input type="text" value="1000"/>	Preference for biting indoors <input type="text" value="High"/>	ITN population usage in last survey (%) <input type="text" value="0% usage"/>
Seasonality of transmission <input type="text" value="Seasonal"/>	Preference for biting people <input type="text" value="Low"/>	What was the estimated coverage of spray campaign (last year) <input type="text" value="0% coverage"/>
Current malaria prevalence <input type="text" value="26-35%"/>	Level of pyrethroid resistance <input type="text" value="0%"/>	<a href="#">How to use these settings</a>
<a href="#">How to use these settings</a>	Evidence of PBO synergy <input type="text" value="Yes"/>	
	<a href="#">How to use these settings</a>	

[Next](#)

The user can enter the appropriate information to set up the baseline scenario that best represents the region. The region of interest is summarised using a limited number of key characteristics. Numbers are currently limited for computational reasons though these are set to expand to include a greater range of scenarios. The user selects characteristics most representative of the current situation based on recent local data. All inputs can be approximations though users are encouraged to experiment with multiple values to understand how different factors influence the optimal decision. The information buttons can be pressed to provide additional help to fill in the form.

### 2.1.1 Population size

Enter the approximate population size of the district or sub-district to which vector control will be applied. This is only necessary if estimates of the overall budget and impact are needed. Otherwise default levels left.

### 2.1.2 Seasonality of transmission

Select the *seasonal* settings if the region of interest has a distinct transmission season, or *perennial* if transmission is throughout the year.

### 2.1.3 Current malaria prevalence

Define the average current endemicity of the setting as measured by the percentage of children under 5-years of age who are diagnosed with *falciparum* malaria by microscopy. Available options are approximately 5% of children under 5 are malaria positive (2.6 – 7.5%); then 7.6 – 15%, 15.1 – 25%, 25.1 – 35%, 35.1 – 45%, 45.1 – 55%, and 55.1- 70% prevalence in children under 5-years of age as measured during the transmission season.

**Site Inputs**

Population Size

1000

Seasonality of transmission ?

Seasonal

Current malaria prevalence ?

26-35%

i How to use these settings ^

**Population size**

Enter the approximate population size of the district or sub-district to which vector control will be applied to enable incremental cost estimates of any change in vector control.

**Seasonality of transmission**

Select seasonal settings if the region of interest has a distinct transmission season or perennial if transmission is throughout the year.

**Current malaria prevalence**

Define the current endemicity of your setting as measured by the prevalence of children 6-month to 59-months of age who are diagnosed with falciparum malaria by microscopy. Available options are <=7%, 8-15%, 16-25%, 26-35%, 36-45%, 46-55% and >=56% as measured toward the end of the transmission season.

Values chosen should represent the ‘average mosquito’ transmitting malaria throughout the year within the zone. If multiple vectors are present, then the characteristics should be weighted towards the dominant vector species. For example, consider a location where two mosquito species A and B are present and are caught throughout the year at a ratio of 3:1 (i.e. Species A = 75%, Species B = 25%). If species A exhibited high levels of resistance with bioassay survival of 80% whilst species B was completely susceptible then the overall level of resistance should be 60% ( $0.75 \times 0.8 + 0.25 \times 0$ ).

#### 2.1.4 Preference for biting indoors

Mosquitoes may show differing propensity to bite people when they are indoors. This depends on both mosquito biting behaviour and when people go indoors. Details for calculating this quantity can be found in (19). A value of *High* indicates ~97% bites taken when people are indoors, whilst selecting *Low* represents 79% bites taken when people are indoors.

#### 2.1.5 Preference for biting people

Mosquitoes show different preference for biting humans relative to other animals (often referred to as the human blood index) (20). A *high* value for the preference for biting people corresponds to ~92% of mosquito bites that are taken on humans prior to introduction of interventions whilst a *low* value equates to ~74% of all bites taken on humans.

### 2.1.6 Level of pyrethroid resistance

Mosquito survival in 24-hour WHO discriminatory dose bioassays; 0% indicates all mosquitoes die and are susceptible to the pyrethroid insecticide in ITNs. 100% indicates all mosquitoes survive and are resistant to the pyrethroid insecticide in ITNs. Estimates should be adjusted taking into account mortality in the control (unexposed) mosquitoes (21,22).

#### Mosquito Inputs

Preference for biting indoors ?

High

Preference for biting people ?

Low

Level of pyrethroid resistance ?

0%

Evidence of PBO synergy ?

Yes

How to use these settings

### 2.1.7 Evidence of PBO synergy

If there is evidence that PBO (piperonyl butoxide) synergises pyrethroid insecticide or that metabolic mechanisms contribute resistance in the local mosquito population then we can select 'Yes' and the pyrethroid PBO ITN will be expected to perform well relative to the pyrethroid LLIN under scenarios with pyrethroid resistance

### 2.1.8 Past Vector Control

The endemicity of a setting is determined by the mosquito ecology, community activities and environment but also the historic pressure from interventions that are controlling malaria transmission. This information needs to be provided for the zone for both ITNs and IRS.

#### Past Vector Control

ITN population usage in last survey (%) ?

0% usage

What was the estimated coverage of spray campaign (last year) ?

0% coverage

How to use these settings

### 2.1.9 ITN population usage in last survey (%)

This can be estimated from Demographic Health Surveys or other surveys on net use completed in this zone.

### 2.1.10 What was the estimated coverage of the recent spray campaign

Please choose the option that best represents the percentage of homes sprayed within the zone during the last IRS campaign. Select option from the drop-down tab. If spraying has never been implemented, please select 0% option.

We will demonstrate a scenario that has:

- ✓ a population of 35,400 people,
- ✓ seasonal transmission with approximately 30% prevalence in children under 5 years of age.

Mosquito behaviours are:

- ✓ highly endophilic,
- ✓ less anthropophilic, and;
- ✓ approximately 60% of mosquitoes are shown to be surviving exposure to a discriminatory dose bioassay (60% pyrethroid resistance).
- ✓ There is evidence of PBO synergy - so that we would expect pyrethroid-PBO ITNs to perform advantageously to pyrethroid LLINs in this scenario.

Historically:

- ✓ about 40% of the community have been using mosquito nets, but;
- ✓ no IRS has been used in the region.

Intervention coverage potential

Expected ITN population use given access ?

60% usage

Expected IRS\* coverage ?

0% coverage

How to use these settings

Setup baseline ▲

Site Inputs	Mosquito Inputs	Past Vector Control
Population Size <input type="text" value="34500"/>	Preference for biting indoors ? <input type="text" value="High"/>	ITN population usage in last survey (%) ? <input type="text" value="40% usage"/>
Seasonality of transmission ? <input type="text" value="Seasonal"/>	Preference for biting people ? <input type="text" value="Low"/>	What was the estimated coverage of spray campaign (last year) ? <input type="text" value="0% coverage"/>
Current malaria prevalence ? <input type="text" value="26-35%"/>	Level of pyrethroid resistance ? <input type="text" value="60%"/>	<div>How to use these settings</div>
<div>How to use these settings</div>	Evidence of PBO synergy ? <input type="text" value="Yes"/>	<div>How to use these settings</div>

## 2.2 Set up interventions

After clicking on the 'next' tab, on the left of the screen, the user can enter the expected ITN use moving forward, and explore the option of including IRS.

### 2.2.1 Expected ITN usage

User enters the expected ITN usage (of any net type: pyrethroid LLIN or pyrethroid-PBO ITN) of people in the community after mass distribution given the procurement and distribution assumptions made in 2.2. This will determine the intervention efficacy over the next period and should be based on what usage was achieved after the last mass campaign (and can be assessed by local or Demographic Health surveys). Only one net type is implemented across the zone and the model assumes there is a loss of ITN use over time since the mass campaign. This loss accounts for both the waning efficacy of the active ingredient and the waning adherence to ITN use.

### 2.2.2 Expected IRS coverage

Indoor residual spraying can be added to a region instead of, or in addition to, ITNs (of any type). Houses to receive IRS are selected at random (irrespective of ITN ownership) and IRS coverage estimates represent the percentage of the population living in houses with IRS. Care should be taken interpreting results as IRS is often highly clustered within small geographical areas. The model predicts the impact of a long-lasting IRS product (for example pirimiphos methyl or clothianidin) where spraying is repeated annually prior to the peak of the transmission season (if seasonal setting selected in 2.1.2).

Intervention coverage potential

Expected ITN population use given access ?

60% usage

Expected IRS\* coverage ?

0% coverage

How to use these settings

## 2.3 Procurement and distribution

The delivery of nets and sprays is conducted differently in each country. Please answer the following questions so that the price estimates for impact can be augmented appropriately.

### 2.3.1 When planning procurement, what number of people per net is used?

The default estimate of 1.8 people per net is most commonly cited as the number used for planning mass distributions of nets. Please change as necessary.

### 2.3.2 What percentage is your procurement buffer, if used?

When mosquito nets are procured, there is a buffer to ensure there is not a short fall. Please indicate your estimate here. This is used to adjust cost estimates. The default is 7%.

Procurement and distribution

When planning procurement, what number of people per net is used?

1.8

What percentage is your procurement buffer, if used? (%)

7

How to use these settings



## 2.4 Price of interventions

The price of different vector control interventions will vary over time, according to the size of orders and specifications. Here quoted prices can be defined by the user in \$USD. For simplicity, it is assumed that there is a linear relationship between cost and population coverage, we do not consider inflation in this version of the tool. Costs of the product and of its delivery are separated.

Price of interventions

Price of pyrethroid LLIN (\$USD)

1.5

Price of PBO ITN (\$USD)

2.5

ITN mass distribution campaign delivery cost per person (\$USD)

2.75

Annual cost of IRS\* per person (\$USD) ?

5.73

How to use these settings

### 2.4.1 Price of pyrethroid LLIN (\$USD)

Price per pyrethroid-only LLIN. The default is set at \$1.5 USD.

### 2.4.2 Price of pyrethroid-PBO ITN (\$USD)

Price per pyrethroid-PBO ITN. The default is set at \$2.5 USD.

### 2.4.3 ITN mass distribution campaign delivery cost per person (\$USD)

Cost to deliver nets to each person (equivalent for each ITN type). Enough nets are provided to match the number of people per net and (2.2.2) the procurement buffer (2.2.3).

### 2.4.4 Price of IRS product per person (annual \$USD)

The price per person of long-lasting IRS product averaged for each year. Include the average cost for both the IRS product and implementation of IRS. If different IRS products are used in different years, please average the product costs and provide an annual cost per person protected by IRS (in \$USD).


### 3 INTERPRETATION

There are 4 outputs tabs in the tool. The:

- (1) Impact
- (2) Cost-Effectiveness
- (3) Summary Impact Table
- (4) Summary Cost-Effectiveness Table

#### 3.1 Impact graphs


The Impact tab shows the estimated prevalence in the zone over time, and the cases averted per 1,000 people across the 3 years since implementing an intervention package.



Top panel – Predicted changes in prevalence of malaria in children <5 years of age (diagnosed by slide positivity) given an intervention package introduced at time 0 (vertical grey line). Lines show either:

- Do-nothing scenario – No additional vector control interventions. Prevalence may rise as impact of previous interventions (if used) are lost (grey);
- Pyrethroid-only LLINs distributed in a mass campaign at time zero (blue);
- Pyrethroid-PBO ITNs distributed in a mass campaign at time zero (green);
- Annual IRS campaign with no additional ITN distribution (purple);
- Annual IRS campaign plus pyrethroid-only ITNs distributed in a mass campaign at time zero (dark red), or;
- Annual IRS campaign plus pyrethroid-PBO ITNs distributed in a mass campaign at time zero (orange).

The lines for IRS will only show if IRS cover is selected to be > 0%.



Lower panel, barchart showing the number of clinical cases averted per 1,000 people averaged over 3 years for the different intervention packages outlined above (relative to the 'do-nothing' scenario).

The impact figures present the different intervention scenarios for the specified zone without considering cost.

Hovering the cursor over the figures will show absolute estimates and uncertainty for the impact of the strategies.

### 3.2 Impact Table

All data presented in the *Impact* figure is summarised in the *Summary Impact Table* tab. This format allows different summary measures to be examined over the three-year time period. Table can be ordered according to the users metric of preference by clicking on the arrows on the different columns.

**Interventions:** The ITN and IRS combination used for the scenario.

**Net use (%):** The percentage of people predicted to use an ITN the previous night following a mass campaign.

**IRS cover (%):** The percentage of people sleeping in an IRS protected home.

**Prevalence under 5 yrs: Yr 1 post intervention:** The prevalence in children under 5 years old 1 year after the intervention package is implemented (percentage, detected by microscopy).

**Prevalence under 5 yrs: Yr 2 post intervention:** The prevalence in children under 5 years old 2 years after the intervention package is implemented (percentage, detected by microscopy).

**Prevalence under 5 yrs: Yr 3 post intervention:** The prevalence in children under 5 years old 3 years after the intervention package is implemented (percentage, detected by microscopy).

**Relative reduction in prevalence in under 5 yrs (%):** The relative efficacy of the investigated intervention package against the 'do-nothing' scenario at 3-years after switching to the alternative interventions.

**Cases averted (all-age) across 3-yrs since intervention:** The absolute number of clinical cases averted given the population size inputted and relative to the 'do-nothing' scenario.

**Mean cases averted (all-age) per 1,000 people per year (across 3-yrs since intervention):** The mean number of clinical cases averted annually per 1,000 people per year relative to the 'do-nothing' scenario.

**Relative reduction in clinical cases (across 3-yrs since intervention) (%):** The percentage-efficacy of the intervention package against reducing the number of clinical cases relative to the 'do-nothing' scenario.

**Mean cases per person per year (averaged across 3-yrs since intervention):** The predicted number of clinical cases per person.

Hovering the cursor over the values in the table will show absolute estimates and uncertainty for the impact of the strategies.

### 3.3 Cost effectiveness Graphs

The Cost effectiveness tab shows the estimated total cost in USD per intervention strategy over 3-years against the expected total number of cases averted per 1,000 people across 3-years (top panel).



The red horizontal dashed line is showing the maximum budget determined by the user for the zone (if provided). Interventions above this line would therefore be considered out of budget so the point furthest to the right beneath this line would indicate the most cost-effective strategy (if no red line is shown the y-axis scale does not intercept this value).

In the scenario demonstrated, the cost-effective strategy within budget would be to use pyrethroid-PBO ITNs, but this may change were the net usage altered or were the different ecologies and assumptions made about the region to be adjusted.

Points show the best estimate for predicted impact whilst the horizontal lines from these points indicate uncertainty in intervention impact driven by the statistical analysis of the interventions (Nash et al. in submission; Sherrard-Smith et al. in submission). Colours denote the different intervention strategies and match those outlined above (and see legend). Uncertainty in costs are not provided in version 1.

Summary information provided by the user indicates the expected ITN usage and IRS coverage to be achieved in the zone. Altering these would alter the cost-effectiveness and the user is encouraged to explore this feature.

### 3.4 Cost effectiveness Table

The cost effectiveness table provides the numbers for the different measures projected by the model. As with the impact table the different intervention packages can be ordered according to the different metrics by clicking on the arrows in each column (to order them by that measure).

**Interventions** The ITN and IRS combination used for the scenario.

**Net use (%):** The percentage of people predicted to use an ITN the previous night following a mass campaign.

**IRS cover (%):** The percentage of people sleeping in an IRS protected home.

**Mean cases averted per 1,000 people per year (averaged across 3-yrs since intervention):** The predicted number of clinical cases per 1,000 people averted by the intervention package relative to the continuation of the 'do-nothing' scenario.

**Total costs \$USD:** The total cost in USD expected for the product procurement and implementation for the intervention package to cover a 3-year period of protection.

**Cost per case averted:** The cost in USD per case averted relative to the 'do-nothing' scenario.

## References

1. Hancock PA, Hendriks CJM, Tangena JA, Gibson H, Hemingway J, Coleman M, et al. Mapping trends in insecticide resistance phenotypes in African malaria vectors. *PLoS Biol* [Internet]. 2020;18(6):1–23. Available from: <http://dx.doi.org/10.1371/journal.pbio.3000633>
2. Matowo NS, Munhenga G, Tanner M, Coetzee M, Feringa WF, Ngowo HS, et al. Fine-scale spatial and temporal heterogeneities in insecticide resistance profiles of the malaria vector, *Anopheles arabiensis* in rural south-eastern Tanzania. *Wellcome open Res* [Internet]. 2017 [cited 2018 Jul 27];2:96. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29417094>
3. Mzilahowa T, Chiumia M, Mbewe RB, Uzalili VT, Luka-Banda M, Kutengule A, et al. Increasing insecticide resistance in *Anopheles funestus* and *Anopheles arabiensis* in Malawi, 2011–2015. *Malar J* [Internet]. 2016 Dec 22 [cited 2018 Jul 27];15(1):563. Available from: <http://malariajournal.biomedcentral.com/articles/10.1186/s12936-016-1610-1>
4. Urabayala S, Kamaraju R, Tiwari S, Ghosh SK, Valecha N. Small-scale evaluation of the efficacy and residual activity of alpha-cypermethrin WG (250 g AI/kg) for indoor spraying in comparison with alpha-cypermethrin WP (50 g AI/kg) in India. *Malar J* [Internet]. 2015;14(1):223. Available from: <http://www.malariajournal.com/content/14/1/223>
5. Etang J, Nwane P, Mbida J, Piamieu M, Manga B, Souop D, et al. Variations of insecticide residual bio-efficacy on different types of walls: results from a community-based trial in south Cameroon. *Malar J* [Internet]. 2011;10(1):333. Available from: <http://www.malariajournal.com/content/10/1/333>
6. Opiyo MA, Paaijmans KP. “We spray and walk away”: Wall modifications decrease the impact of indoor residual spray campaigns through reductions in post-spray coverage. *Malar J* [Internet]. 2020;19(1):1–6. Available from: <https://doi.org/10.1186/s12936-020-3102-6>
7. Griffin JT, Ferguson NM, Ghani AC. Estimates of the changing age-burden of *Plasmodium falciparum* malaria disease in sub-Saharan Africa. *Nat Commun* [Internet]. 2014;5:1–10. Available from: <http://dx.doi.org/10.1038/ncomms4136>
8. Walker PGT, Griffin JT, Ferguson NM, Ghani AC. Estimating the most efficient allocation of interventions to achieve reductions in *Plasmodium falciparum* malaria burden and transmission in Africa: a modelling study. *Lancet Glob Heal* [Internet]. 2016 Jul 1 [cited 2018 Dec 12];4(7):e474–84. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27269393>
9. Unwin HJT, Routledge I, Flaxman S, Rizoio M-A, Lai S, Cohen J, et al. Using Hawkes Processes to model imported and local malaria cases in near-elimination settings. *PLOS Comput Biol* [Internet]. 2021 Apr 1 [cited 2021 Sep 27];17(4):e1008830. Available from: <https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1008830>
10. Pezzulo C, Hornby GM, Sorichetta A, Gaughan AE, Linard C, Bird TJ, et al. Sub-national mapping of population pyramids and dependency ratios in Africa and Asia. *Sci Data* 2017 41 [Internet]. 2017 Jul 19 [cited 2021 Sep 1];4(1):1–15. Available from: <https://www.nature.com/articles/sdata201789>
11. Staedke SG, Gonahasa S, Dorsey G, Kanya MR, Maiteki-Sebuguzi C, Lynd A, et al. Effect of long-lasting insecticidal nets with and without piperonyl butoxide on malaria indicators in Uganda (LLINEUP): a pragmatic, cluster-randomised trial embedded in a national LLIN distribution campaign. *Lancet* [Internet]. 2020;395(10232):1292–303. Available from: [http://dx.doi.org/10.1016/S0140-6736\(20\)30214-2](http://dx.doi.org/10.1016/S0140-6736(20)30214-2)
12. Nash RK, Lambert B, N’Guessan R, Ngufor C, Rowland M, Oxborough R, et al. Systematic

- review of the entomological impact of insecticide-treated nets evaluated using experimental hut trials in Africa. *Curr Res Parasitol Vector-Borne Dis*. 2021 Jan 1;1:100047.
13. Sherrard-Smith E, Griffin JT, Winskill P, Corbel V, Pennetier C, Djénontin A, et al. Systematic review of indoor residual spray efficacy and effectiveness against *Plasmodium falciparum* in Africa. *Nat Commun* [Internet]. 2018 Dec 26 [cited 2019 Jul 10];9(1):4982. Available from: <http://www.nature.com/articles/s41467-018-07357-w>
  14. Griffin JT, Hollingsworth TD, Okell LC, Churcher TS, White M, Hinsley W, et al. Reducing *Plasmodium falciparum* malaria transmission in Africa: a model-based evaluation of intervention strategies. *PLoS Med* [Internet]. 2010 Aug 10 [cited 2017 Jan 13];7(8):e1000324. Available from: <http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1000324>
  15. Bertozzi-Villa A, Bever C, Koenker H, Weiss DJ, Vargas-Ruiz C, Nandi AK, et al. Maps and Metrics of Insecticide-Treated Net Coverage in Africa: Access, Use, and Nets-Per-Capita, 2000-2020 [Internet]. 2021 Feb [cited 2021 May 4]. Available from: <https://www.researchsquare.com/article/rs-199628/v1.pdf>
  16. West PA, Protopopoff N, Wright A, Kivaju Z, Tigererwa R, Mosha FW, et al. Enhanced protection against malaria by indoor residual spraying in addition to insecticide treated nets: Is it dependent on transmission intensity or net usage? *PLoS One*. 2015 Mar 26;10(3).
  17. Chaccour C, Zulliger R, Wagman J, Casellas A, Nacima A, Elobolobo E, et al. Incremental impact on malaria incidence following indoor residual spraying in a highly endemic area with high standard ITN access in Mozambique: results from a cluster-randomized study. *Malar J* [Internet]. 2021 Dec 1 [cited 2021 Jun 27];20(1):1–15. Available from: <https://doi.org/10.1186/s12936-021-03611-7>
  18. Protopopoff N, Mosha JF, Lukole E, Charlwood JD, Wright A, Mwalimu CD, et al. Effectiveness of a long-lasting piperonyl butoxide-treated insecticidal net and indoor residual spray interventions, separately and together, against malaria transmitted by pyrethroid-resistant mosquitoes: a cluster, randomised controlled, two-by-two fact. *Lancet* [Internet]. 2018 Apr 21 [cited 2018 Jul 26];391(10130):1577–88. Available from: <https://www.sciencedirect.com/science/article/pii/S0140673618304276>
  19. Sherrard-Smith E, Skarp JE, Beale AD, Fornadel C, Norris LC, Moore SJ, et al. Mosquito feeding behavior and how it influences residual malaria transmission across Africa. *Proc Natl Acad Sci U S A*. 2019;116(30):15086–96.
  20. Killeen GF, Kiware SS, Okumu FO, Sinka ME, Moyes CL, Massey NC, et al. Going beyond personal protection against mosquito bites to eliminate malaria transmission: population suppression of malaria vectors that exploit both human and animal blood. *BMJ Glob Heal* [Internet]. 2017 Apr 26 [cited 2019 Jun 19];2(2):e000198. Available from: <http://gh.bmj.com/lookup/doi/10.1136/bmjgh-2016-000198>
  21. Churcher TS, Lissenden N, Griffin JT, Worrall E, Ranson H. The impact of pyrethroid resistance on the efficacy and effectiveness of bednets for malaria control in Africa. *Elife*. 2016 Aug 22;5.
  22. World Health Organization. Malaria vector control policy recommendations and their applicability to product evaluation [Internet]. 2017 [cited 2018 Jan 18]. Available from: <http://apps.who.int/iris/bitstream/10665/255337/1/WHO-HTM-GMP-2017.12-eng.pdf?ua=1>